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Definition
(Bronchial) Asthma is defined as a chronic inflammatory disorder of the 
airways which characterized by bronchial hyper-responsiveness and 
variable airflow obstruction, that is often reversible either 
spontaneously or with treatment, and manifests itself as recurrent 
episodes of wheezing, breathlessness, chest tightness and cough, that 
may occur a few times a day or a few times per week and depending on 
the person may become worse at night or with exercise.
https ://en.wikipedia.org/wiki/Asthma ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
Global Initiative for Asthma (GINA)
In 1992, WHO and the US-based National Heart, Lung and Blood 
Institute jointly formed GINA to cut deaths and disability by developing 
and implementing an optimal strategy for asthma management and 
prevention. Since its inception GINA has:
• produced a report covering a range of information detailing all the 
latest knowledge on causes, the mechanism, risk factors, 
management, education and socio-economic factors 
• developed guidelines on asthma management  
• held workshops to introduce the GINA program to public health 
officials and medical professionals  
GINA's goal is to build an active network with multiple organizations 
concerned with asthma to ensure better patient care world-wide.
http://www.who.int/mediacentre/factsheets/fs206/en/
Epidemiology
• Asthma is one of the most common chronic diseases worldwide
• There are about 315 million people estimated to be suffering from 
asthma worldwide
• The global prevalence of asthma, using a definition of clinical asthma 
or treated asthma, is estimated to be about 4.5% 
• Using a less rigorous definition for diagnosis of asthma, the global 
prevalence is approximately 8.6%
• There has been an increase in prevalence of asthma over time, 
similar to other allergic disorders.
• An additional 100 million people worldwide are likely to develop 
asthma, by 2025
https ://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
Epidemiology
http://www.nature.com/nri/journal/v6/n11/images/nri1958-f3.jpg
Epidemiology
http://image.slidesharecdn.com/ginamodified-090721100743-phpapp02/95/gina-global-initiative-against-asthma-14-728.jpg?cb=1248170947
Risk Factors and Etiology    
• Asthma is caused by a combination of complex and incompletely 
understood environmental and genetic interactions
• These factors influence both asthma severity and asthma 
responsiveness to treatment
• It is believed that the recent increased rates of asthma are due to 
changing epigenetics (heritable factors other than those related to 
the DNA sequence) and a changing living environment
• Onset before age 12 is more likely due to genetic influence, while 
onset after 12 is more likely due to environmental influence.
https://en.wikipedia.org/wiki/Asthma#Causes
Risk Factors and Etiology          
Environmental
https://en.wikipedia.org/wiki/Asthma#Causes
• Smoking during pregnancy and after delivery is associated with a 
greater risk of asthma-like symptoms
• Low air quality (traffic pollution or high ozone levels) has been 
associated with asthma development and increased asthma severity 
• Exposure to indoor volatile organic compounds may be a trigger for 
asthma (formaldehyde, phthalates, etc.)
• There is an association between acetaminophen (paracetamol) use 
and asthma  
• Exposure to indoor allergens (dust mites, cockroaches, animal 
dander, and mold.) 
• Certain viral respiratory infections (respiratory syncytial virus and 
rhinovirus)
• Certain other infections, however, may decrease the risk.
Risk Factors and Etiology                
Hygiene Hypothesis
https://en.wikipedia.org/wiki/Asthma#Causes
• The increased rates of asthma worldwide as a direct and unintended 
result of reduced exposure, during childhood, to non-pathogenic 
bacteria and viruses
• The reduced exposure to bacteria and viruses is due, in part, to 
increased cleanliness and decreased family size in modern societies
• Exposure to bacterial endotoxin in early childhood may prevent the 
development of asthma, but exposure at an older age may provoke 
bronchoconstriction 
• Use of antibiotics in early life has been linked to the development of 
asthma
• Also, delivery via caesarean section is associated with an increased 
risk (estimated at 20–80%) of asthma
• There is a link between asthma and the degree of affluence.
Risk Factors and Etiology                
Genetic
https://en.wikipedia.org/wiki/Asthma#Causes
• Family history is a risk factor for asthma, with many different genes 
being implicated
• If one identical twin is affected, the probability of the other having 
the disease is approximately 25%
• By the end of 2005, 25 genes had been associated with asthma in six 
or more separate populations, including GSTM1, IL10, CTLA-
4, SPINK5, LTC4S, IL4R and ADAM33, among others
• Some genetic variants may only cause asthma when they are 
combined with specific environmental exposures.
Risk Factors and Etiology                
Medical Conditions
https://en.wikipedia.org/wiki/Asthma#Causes
• A triad of atopic eczema, allergic rhinitis and asthma is called atopy
• The risk factor for developing asthma is a history of atopic disease
• Asthma has been associated with eosinophilic granulomatosis with 
polyangiitis (formerly known as Churg–Strauss syndrome), an 
autoimmune disease and vasculitis
• Individuals with urticaria may also experience symptoms of asthma
• There is a correlation between obesity and the risk of asthma 
• Beta blocker medications can trigger asthma in those who are 
susceptible
• Other medications that can cause problems in asthmatics 
are angiotensin-converting enzyme inhibitors, aspirin, and NSAIDs.
Risk Factors and Etiology                
Exacerbation
https://en.wikipedia.org/wiki/Asthma#Causes
• Some individuals will have stable asthma for weeks or months and 
then suddenly develop an episode of acute asthma
• Different individuals react to various factors in different ways
• Most individuals can develop severe exacerbation from a number of 
triggering agents
• Home factors that can lead to exacerbation of asthma include dust, 
cat and dog hair, etc. 
• Perfumes are a common cause of acute attacks in women and 
children
• Both viral and bacterial infections of the upper respiratory tract can 
worsen the disease
• Psychological stress may worsen symptoms.
Risk Factors and Etiology                
Triggers
http://image.slidesharecdn.com/presentation6-140430130846-phpapp02/95/bronchial-asthma-13-638.jpg?cb=1398952028
Mechanism
• The mechanism involves airway inflammation, intermittent airflow 
obstruction, and bronchial hyperresponsiveness
• Varying degrees of mononuclear cell and eosinophil infiltration, 
mucus hypersecretion, desquamation of the epithelium, smooth 
muscle hyperplasia, and airway remodeling are present
• Airway hyperresponsiveness or bronchial hyperreactivity is an 
exaggerated response to numerous stimuli
• The mechanisms include direct stimulation of airway smooth muscle 
and indirect stimulation by pharmacologically active substances from 
mediator-secreting cells (mast cells, nonmyelinated sensory neurons)
• The degree of airway hyperresponsiveness correlates with the 
severity of asthma.  
http://emedicine.medscape.com/article/296301-overview#a2
Mechanism                                           
Airway Inflammation 1
• The mechanism of inflammation in asthma may be acute, subacute, 
or chronic, and the presence of airway edema and mucus secretion 
also contributes to airflow obstruction and bronchial reactivity 
• Some of the principal cells identified in airway inflammation include 
mast cells, eosinophils, epithelial cells, macrophages, and activated T 
lymphocytes. 
• Other constituent airway cells, such as fibroblasts, endothelial cells, 
and epithelial cells, contribute to the chronicity of the disease
• Other factors, such as adhesion molecules (e.g., selectins, integrins), 
are critical in directing the inflammatory in the airway
• Cell-derived mediators influence smooth muscle tone and produce 
structural changes and remodeling of the airway  
http://emedicine.medscape.com/article/296301-overview#a4
Mechanism                                           
Airway Inflammation 2
• The presence of airway hyperresponsiveness or bronchial 
hyperreactivity in asthma is an exaggerated response to numerous 
exogenous and endogenous stimuli
• The mechanisms include direct stimulation of airway smooth muscle 
and indirect stimulation by pharmacologically active substances from 
mediator-secreting cells  (e.g., mast cells, sensory neurons)
• Airway inflammation may represent a loss of normal balance 
between two "opposing" populations of Th lymphocytes (Th1 and 
Th2) with cytokine imbalance
• The degree of airway hyperresponsiveness correlates with the clinical 
severity of asthma.   
http://emedicine.medscape.com/article/296301-overview#a4
Mechanism                                           
Mechanism of 
asthma. Antigen 
presentation by the 
dendritic cell with 
the lymphocyte and 
cytokine response 
leading to airway 
inflammation and 
asthma symptoms.
http://emedicine.medscape.com/article/296301-overview
Mechanism                                           
Airflow Obstruction  
• Airflow obstruction can be caused by a variety of changes, including 
acute bronchoconstriction, airway edema, chronic mucous plug 
formation, and airway remodeling 
• Acute bronchoconstriction is the consequence of immunoglobulin E-
dependent mediator release upon exposure to aeroallergens and is 
the primary component of the early asthmatic response
• Chronic mucous plug formation consists of an exudate of serum 
proteins and cell debris that may take weeks to resolve 
• Airway remodeling may profoundly affect the extent of reversibility of 
airway obstruction 
• Airway obstruction causes increased resistance to airflow and 
decreased expiratory flow rates.  
http://emedicine.medscape.com/article/296301-overview#a4
Mechanism                                           
Bronchial Hyperresponsiveness 1 
• Hyperinflation compensates for the airflow obstruction, but this 
compensation is limited when the tidal volume approaches the 
volume of the pulmonary dead space; the result is alveolar 
hypoventilation
• Uneven changes in airflow resistance, the resulting uneven 
distribution of air, and alterations in circulation from increased intra-
alveolar pressure due to hyperinflation all lead to ventilation-
perfusion mismatch
• Vasoconstriction due to alveolar hypoxia also contributes to this 
mismatch
• Vasoconstriction is also considered an adaptive response to 
ventilation/perfusion mismatch  
http://emedicine.medscape.com/article/296301-overview#a4
Mechanism                                           
Bronchial Hyperresponsiveness 2 
• In the early stages, when ventilation-perfusion mismatch results in 
hypoxia, hypercarbia is prevented by the ready diffusion of carbon 
dioxide across alveolar capillary membranes and patients  have 
hypoxemia in the absence of carbon dioxide retention
• Hyperventilation triggered by the hypoxic drive also causes a 
decrease in PaCO2
• With worsening obstruction and increasing ventilation-perfusion 
mismatch, carbon dioxide retention occurs
• Later, the increased work of breathing, increased oxygen 
consumption, and increased cardiac output result in metabolic 
acidosis
• Respiratory failure leads to respiratory acidosis due to retention of 
carbon dioxide as alveolar ventilation decreases.
http://emedicine.medscape.com/article/296301-overview#a4
Classification 
International Classification of Diseases  
http://apps.who.int/classifications/icd10/browse/2016/en#/J45
• X Diseases of the respiratory system
• J45 Asthma
• J45.0 Predominantly allergic asthma
• J45.1 Nonallergic asthma
• J45.8 Mixed asthma
• J45.9 Asthma, unspecified
• J46 Status asthmaticus
Classification
The National Asthma Education and Prevention Program
http://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview
• Intermittent 
• Mild persistent 
• Moderate persistent 
• Severe persistent 
Classification is based on symptoms before treatment 
Classification may change over time 
A person in any category can have severe asthma attacks 
Asthma in children younger than age 4 can be hard to diagnose and its 
symptoms may be different from asthma in older children or adults.
Classification
Clinical
https ://en.wikipedia.org/wiki/Asthma#Diagnosis
Severity
Symptom 
frequency
Night time 
symptoms
%FEV1 of 
predicted
FEV1Vari
ability
SABA use
Intermittent ≤2/week ≤2/month ≥80% <20%
≤2 
days/week
Mild 
persistent
>2/week 3–4/month ≥80% 20–30%
>2 
days/week
Moderate 
persistent
Daily >1/week 60–80% >30% daily
Severe 
persistent
Continuously
Frequent 
(7×/week)
<60% >30% ≥twice/day
Symptoms and Signs
• Asthma is characterized by recurrent episodes of wheezing, shortness 
of breath, chest tightness, and coughing
• Sputum may be produced from the lung by coughing but is often hard 
to bring up
• During recovery from an attack, it may appear pus-like due to high 
levels of white blood cells called eosinophils
• Symptoms are usually worse at night and in the early morning 
(bronchoconstriction is highest between the hours of 4:00 am and 
6:00 am (the highest morbidity and mortality from asthma is 
observed during this time)) or in response to exercise or cold air
• Some people with asthma rarely experience symptoms, usually in 
response to triggers, whereas others may have marked and persistent 
symptoms.
https://en.wikipedia.org/wiki/Asthma#Signs_and_symptoms
Clinical Manifestations 
Intermittent Asthma
• Symptoms (difficulty breathing, wheezing, chest tightness, 
and coughing):
– Occur on fewer than 2 days a week 
– Do not interfere with normal activities 
• Nighttime symptoms occur on fewer than 2 days a month 
• Lung function tests (spirometry and peak expiratory flow[PEF]) are 
normal when the person is not having an asthma attack (the results 
of these tests are 80% or more of the expected value and vary little 
(PEF varies less than 20%) from morning to afternoon).
http://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview
Clinical Manifestations 
Mild persistent Asthma
• Symptoms occur on more than 2 days a week but do not occur every 
day 
• Attacks interfere with daily activities 
• Nighttime symptoms occur 3 to 4 times a month 
• Lung function tests are normal when the person is not having an 
asthma attack (the results of these tests are 80% or more of the 
expected value and may vary a small amount (PEF varies 20% to 30%) 
from morning to afternoon).
http://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview
Clinical Manifestations 
Moderate persistent Asthma
• Symptoms occur daily, inhaled short-acting asthma medication is 
used every day 
• Symptoms interfere with daily activities 
• Nighttime symptoms occur more than 1 time a week, but do not 
happen every day 
• Lung function tests are abnormal (more than 60% to less than 80% of 
the expected value), and PEF varies more than 30% from morning to 
afternoon.
http://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview
Clinical Manifestations 
Severe persistent Asthma
• Symptoms:
• Occur throughout each day 
• Severely limit daily physical activities 
• Nighttime symptoms occur often, sometimes every night 
• Lung function tests are abnormal (60% or less of expected value), and 
PEF varies more than 30% from morning to afternoon.
http://www.webmd.com/asthma/tc/classification-of-asthma-topic-overview
Clinical Manifestations 
History
• Whether symptoms are attributable to asthma
• Whether  findings support the likelihood of asthma c
• Asthma severity
• Possible precipitating factors
• Family history (asthma, allergy, sinusitis, rhinitis, eczema, nasal polyps)
• The social history (home and workplace characteristics, smoking, 
educational level, employment, social support, factors that may 
contribute to nonadherence of asthma medications, illicit drug use )
• The patient’s exacerbation history (usual prodromal signs or 
symptoms, rapidity of onset, associated illnesses, number in the last 
year, need for emergency department visits, hospitalizations, etc.)
• The patient’s perception of asthma is important regarding knowledge 
of asthma and treatment.
http://emedicine.medscape.com/article/296301-clinical
Clinical Manifestations 
an Acute Episode
• In a mild episode, patients may be breathless after physical activity; 
they can talk in sentences and lie down; the respiratory rate (RR) is 
increased, and accessory muscles of respiration are not used; the 
heart rate (HR) < 100 bpm; auscultation reveals end expiratory
wheezing; oxyhemoglobin saturation (OS) is >95%
• In a moderately severe episode, the RR is increased; accessory 
muscles of respiration are used; HR is 100-120 bpm; loud expiratory 
wheezing can be heard; OS is 91-95%
• In a severe episode, patients are breathless during rest, sit upright, 
talk in words rather than sentences, and are usually agitated; RR >30 
1/m; accessory muscles of respiration are usually used, and 
suprasternal retractions are commonly present; HR is >120 bpm; loud 
expiratory and inspiratory wheezing can be heard; OS <91%. 
http://emedicine.medscape.com/article/296301-clinical#b3
Complications
https://www.welcomecure.com/diseases/bronchial-asthma/complications
• Status asthmaticus or a sustained state of asthma if obstruction 
remains for days and weeks and fails to respond to treatment 
• Pneumonia or infection in the lungs by bacteria or viruses 
• Atelectasis or collapse of a section of the lung can happen if there is 
excessive mucosal blockage in a smaller airway 
• Respiratory failure, where the levels of oxygen in the blood become 
dangerously low, or the levels of carbon dioxide become dangerously 
high 
• Underperformance and fatigue at school, work or in recreational 
occupations is among the commonest complications of asthma 
• Absenteeism from workplace 
• Anxiety, Depression.
Diagnosis
• The diagnosis remains largely clinical due to the absence of a gold 
standard
• The classical symptoms (wheezing, breathlessness, cough, and chest 
tightness) tend to be variable, seasonal, recurrent and/or nocturnal
• Presence of atopy, family history of asthma in a first degree relative, 
and/or symptomatic worsening after exposure to non-specific 
triggers support a diagnosis of asthma
• The presence of expiratory polyphonic wheeze is a typical finding, 
and hyperinflated chest may suggest long-standing disease
• Tachycardia, tachypnea, use of accessory muscles of respiration 
suggest an asthma exacerbation
• When the exacerbation is very severe, marked airflow limitation and 
air trapping may result in a ‘silent chest’ accompanied by signs of 
respiratory failure.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
Diagnosis                                     
Recommendations
• A clinical diagnosis of asthma should be suspected in the presence of 
recurrent/episodic wheezing, breathlessness, cough, and/or chest 
tightness with no alternative explanation for these symptoms 
• None of the symptoms and signs are specific for asthma 
• Absence of signs and symptoms at the time of presentation does not 
rule out the presence of asthma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
Diagnosis                                             
Spirometry 1 1
https://en.wikipedia.org/wiki/Asthma#Diagnosis
• Spirometry is the single best test for asthma
• If the FEV1 measured by this technique improves more than 12% 
following administration of a bronchodilator such as salbutamol, this 
is supportive of the diagnosis
• It however may be normal in those with a history of mild asthma, not 
currently acting up
• As caffeine is a bronchodilator in people with asthma, the use of 
caffeine before a lung function test may interfere with the results
• Single-breath diffusing capacity can help differentiate asthma 
from COPD
• It is reasonable to perform spirometry every one or two years to 
follow how well a person's asthma is controlled.
Diagnosis                                             
Spirometry 2
http://image.slidesharecdn.com/copyofslsqasthmamanagementpptv050811piccomp-141113083910-conversion-gate02/95/spirometry-basics-2-69-638.jpg?cb=1415868230
Diagnosis                                             
Spirometry 3
http://uninursety.com/images/courses/asthma_05.gif
Diagnosis                                             
Chest Radiography
• There is no role for routine chest radiography in a newly diagnosed 
patient of asthma
• A chest radiograph may be warranted when additional complications 
like allergic bronchopulmonary aspergillosis, or an alternative 
diagnosis like tuberculosis, are under consideration
• Presence of increased bronchovascular markings and low diaphragm 
are few features noted in asthmatics more commonly than normal 
individuals; however, these do not differentiate asthma from other 
pulmonary disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
Diagnosis                                             
Imaging Studies  
http://emedicine.medscape.com/article/296301-differential ncbi.nlm.nih.gov/pmc/articles/PMC4405919/
• CT, single-photon emission 
computerized tomography and 
positron emission tomography are 
being investigated to understand 
the pathophysiologic and 
anatomic abnormalities in 
asthmatics
• Currently they have no role in the 
routine diagnosis or management 
of asthma.
Asthma. Recurrent left 
lower lobe pneumonia. 
Mucoepidermoid 
carcinoma. 
Diagnosis                                              
Differentiation
http://emedicine.medscape.com/article/296301-differential
• Allergic and Environmental 
Asthma
• Alpha1-Antitrypsin Deficiency
• Aspergillosis
• Bronchiectasis
• Bronchiolitis
• Chronic Obstructive Pulmonary 
Disease (COPD)
• Chronic Sinusitis
• Eosinophilic Granulomatosis 
with Polyangiitis (Churg-Strauss 
Syndrome)
• Cystic Fibrosis
• Foreign Body Aspiration
• Gastroesophageal Reflux 
Disease
• Heart Failure
• Pediatric Airway Foreign Body
• Pediatric Tracheomalacia
• Pulmonary Embolism
• Pulmonary Eosinophilia
• Sarcoidosis
• Upper Respiratory Tract 
Infection
• Vocal Cord Dysfunction
Management
Approach Considerations 1
• Medical care includes treatment of acute asthmatic episodes and 
control of chronic symptoms, including nocturnal and exercise-
induced asthmatic symptoms
• Pharmacologic management inhaled corticosteroids, long-acting 
bronchodilators (beta-agonists and anticholinergics), theophylline, 
leukotriene modifiers, and more recent strategies such as the use of 
anti-immunoglobulin E (IgE) antibodies (omalizumab) and anti-IL-5 
antibodies in selected patients
• Relief medications include short-acting bronchodilators, systemic 
corticosteroids, and ipratropium.
http://emedicine.medscape.com/article/296301-treatment#d1
Management
Approach Considerations 2
• For all but the most severely affected patients, the ultimate goal is to 
prevent symptoms, minimize morbidity from acute episodes, and 
prevent functional and psychological morbidity to provide a healthy 
(or near healthy) lifestyle
• A stepwise (step-up if necessary and step-down when possible) 
approach to asthma management continues to be used in the current 
guidelines and is now divided into 3 groups based on age (0-4 y, 5-11 
y, 12 y and older)
• The intensity of treatment depends on the severity of symptoms
• If rapid-acting beta2 agonists are used more than 2 days a week for 
symptom relief (not including use of rapid-acting beta2agonists for 
prevention of exercise-induced symptoms), stepping up on treatment 
may need be considered.
http://emedicine.medscape.com/article/296301-treatment#d1
Management
Approach Considerations 3
• The 2015 Global Initiative for Asthma (GINA) guidelines identify 
inhaled corticosteroids as the preferred controller medication of 
choice for children and adults 
• In general, patients should be assessed every 1-6 months for asthma 
control
• At every visit, adherence, environmental control, and comorbid 
conditions should be checked
• If the patient has good control of their asthma for at least 3 months, 
treatment can be stepped down; however, the patient should be 
reassessed in 2-4 weeks to make sure that control is maintained with 
the new treatment.
http://emedicine.medscape.com/article/296301-treatment#d1
Management                                 
The Stepwise Approach to Asthma Therapy
http://www.ajmc.com/journals/supplement/2005/2005-11-vol11-n14suppl/nov05-2212ps416-s421
Management
Environmental Control
• Efforts should focus on the home, where 30-60% of time is spent
• Patients should clean and dust their homes regularly
• If a patient cannot avoid vacuuming, he or she should use a face mask 
or a double-bagged vacuum with a high-efficiency particulate air filter
• If possible, consideration can be given to moving to a higher floor in 
the house or different neighborhood
• Active smoking and exposure to passive smoke must be avoided 
• Air pollution caused by traffic may increase the risk of asthma and 
wheezing, especially in individuals with EPHX1 gene and enzyme 
activity.
http://emedicine.medscape.com/article/296301-treatment#d9
Management                                     
Allergen Immunotherapy
• The use of immunotherapy for the treatment of asthma is 
controversial
• The National Asthma Education and Prevention Program Expert Panel 
Report recommends that immunotherapy be considered if a 
relationship is clear between symptoms and exposure to an 
unavoidable allergen to which the patient is sensitive; symptoms 
occur all year or during a major portion of the year; symptoms are 
difficult to control with pharmacologic management because the 
medication is ineffective, multiple medications are required, or the 
patient is not accepting of medication.
http://emedicine.medscape.com/article/296301-treatment#d10
Management                                     
Monoclonal Antibody Therapy
• Omalizumab (a humanized murine IgG antibody against the Fc 
component of the IgE antibody (the part that attaches to mast cell 
surfaces)) was approved in 2003 for patients ≥12 y with moderate-to-
severe persistent asthma who have a positive skin test result or in 
vitro reactivity to a perennial aeroallergen and whose symptoms are 
inadequately controlled with inhaled corticosteroids
• Mepolizumab (a humanized IgG1 kappa monoclonal antibody specific 
for interleukin 5)  is indicated for add-on maintenance treatment of 
patients ≥ 12 y with severe asthma with an eosinophilic phenotype 
• Reslizumab (an IgG kappa monoclonal antibody that inhibits IL-5) is 
indicated for add-on maintenance treatment of patients with severe 
asthma aged 18 years and older with an eosinophilic phenotype. It is 
administered as an intravenous infusion every 4 weeks.
http://emedicine.medscape.com/article/296301-treatment#d11
Management                                     
Fast–acting Medications
• Short-acting beta2-adrenoceptor agonists (SABA), such 
as salbutamol are the first line treatment for asthma symptomsand
are recommended before exercise in those with exercise induced 
symptoms 
• Anticholinergic medications, such as ipratropium bromide, provide 
additional benefit when used in combination with SABA in those with 
moderate or severe symptoms; they can also be used if a person 
cannot tolerate a SABA 
• Older, less selective adrenergic agonists, such as inhaled epinephrine, 
have similar efficacy to SABAs; they are however not recommended 
due to concerns regarding excessive cardiac stimulation.
https://en.wikipedia.org/wiki/Asthma#Diagnosis
Management                                     
Long–term Control 1
• Corticosteroids are generally considered the most effective treatment 
available for long-term control
• Inhaled forms such as beclomethasone are usually used except in the 
case of severe persistent disease, in which oral corticosteroids may 
be needed; it is usually recommended that inhaled formulations be 
used once or twice daily, depending on the severity of symptoms
• Long-term use of inhaled corticosteroids at conventional doses 
carries a minor risk of adverse effects (development of cataracts and 
a mild regression in stature) 
• Long-acting beta-adrenoceptor agonists (LABA) such as salmeterol 
and formoterol can improve asthma control, at least in adults, when 
given in combination with inhaled corticosteroids; when used 
without steroids they increase the risk of severe side-effectsand even 
with corticosteroids they may slightly increase the risk.  
https://en.wikipedia.org/wiki/Asthma#Diagnosis
Management                                     
Long–term Control 2
• Leukotriene receptor antagonists (such as montelukast and 
zafirlukast) may be used in addition to inhaled corticosteroids, 
typically also in conjunction with a LABA
• A similar class of drugs, 5-LOX inhibitors, may be used as an 
alternative in the chronic treatment of mild to moderate asthma 
among older children and adults 
• Mast cell stabilizers (such as cromolyn sodium) are another non-
preferred alternative to corticosteroids.
https://en.wikipedia.org/wiki/Asthma#Diagnosis
Management                                        
Nebulizers and Spacers
Nebulizer
https://en.wikipedia.org/wiki/Asthma#Diagnosis.wisegeek.com/dry-powder-inhaler.jpg apqualitycare.com/product/nebulizers-spacers/
Spacer
Medications are typically provided as metered-dose inhalers (MDIs) in 
combination with an asthma spacer or as a dry powder inhaler. 
A nebulizer may also be used. Nebulizers and spacers are equally 
effective in those with mild to moderate symptoms.
Dry powder inhaler
Management                                        
Emergency Management
• Oxygen to alleviate hypoxia if saturations fall below 92%
• Corticosteroid by mouth are recommended with five days 
of prednisone being the same 2 days of dexamethasone 
• Magnesium sulfate intravenous treatment increases bronchodilation 
in moderate severe acute asthma attacks 
• Heliox, a mixture of helium and oxygen, may also be considered in 
severe unresponsive cases 
• The dissociative anesthetic ketamine is theoretically useful 
if intubation and mechanical ventilation is needed in people who are 
approaching respiratory arrest; however, there is no evidence from 
clinical trials to support this. 
https://en.wikipedia.org/wiki/Asthma#Diagnosis
Management                                     
Patient Education
• Patient education should be integrated into every aspect of asthma 
care
• All members of the healthcare team, including nurses, pharmacists, 
and respiratory therapists, should provide education 
• Clinicians should teach patients asthma self-management based on 
basic asthma facts, self-monitoring techniques, the role of 
medications, inhaler use, and environmental control measures 
• Treatment goals should be developed for the patient and family 
• A written, individualized, daily self-management plan should be 
developed. 
http://emedicine.medscape.com/article/296301-overview#a8
Prognosis
• International asthma mortality is reported as high as 0.86 deaths per 
100,000 persons in some countries
• Mortality is primarily related to lung function, but it has also been 
linked with asthma management failure, especially in young persons, 
age older than 40 years, cigarette smoking more than 20 pack-years, 
blood eosinophilia, forced expiratory volume in one second (FEV1) of 
40-69% predicted, and greater reversibility 
• The estimate of lost work and school time from asthma is 
approximately 100 million days of restricted activity
• Approximately 500,000 annual hospitalizations (40.6% in individuals 
aged 18 y or younger) are due to asthma 
• Patients with poorly controlled asthma develop long-term changes 
over time (i.e., with airway remodeling). 
http://emedicine.medscape.com/article/296301-overview#a7
Prophylaxis
• Cover bedding with allergy-proof casings to reduce exposure to dust 
mites 
• Remove carpets from bedrooms and vacuum regularly 
• Use only unscented detergents and cleaning materials in the home 
• Keep humidity levels low and fix leaks to reduce the growth of 
organisms such as mold 
• Keep the house clean and keep food in containers and out of 
bedrooms 
• If someone is allergic to an animal that cannot be removed from the 
home, the animal should be kept out of the bedroom 
• Eliminate tobacco smoke from the home   
• Avoid air pollution, industrial dust, and irritating fumes as much as 
possible.
https ://medlineplus.gov/ency/article/000141.htm
Abbreviations 
COPD - Chronic Obstructive Pulmonary Disease
EF - peak expiratory flow 
FEV1 - forced expiratory volume in 1 second
ILO - inducible laryngeal obstruction 
HR - heart rate 
LABA - long-acting beta-adrenoceptor agonists
OS - oxyhemoglobin saturation 
RR - respiratory rate 
SABA - short-acting beta2-adrenoceptor agonists. 
Diagnostic and treatment guidelines
Global Initiative for Asthma - Global Initiative for Asthma - GINA
Asthma Treatment & Management
Guidelines for diagnosis and management of bronchial asthma: Joint 
ICS/NCCP (I) recommendations
International ERS/ATS Guidelines on Definition, Evaluation and 
Treatment of Severe Asthma
BTS/SIGN British guideline on the management of asthma
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